What are the standard chemotherapy regimens for breast cancer based on HER2 and hormone‑receptor status?

Chemotherapy Regimens for Breast Cancer by Subtype

HER2-Positive Breast Cancer

For first-line treatment of HER2-positive advanced breast cancer, use trastuzumab plus pertuzumab plus a taxane unless contraindications exist. 1

First-Line Treatment

• Trastuzumab + pertuzumab + taxane is the standard first-line regimen for HER2-positive disease, representing the strongest evidence-based recommendation 1
• Continue chemotherapy for approximately 4-6 months (or longer) until maximal response, then maintain HER2-targeted therapy alone after stopping chemotherapy 1
• For patients with contraindications to taxanes (such as congestive heart failure), alternative approaches must be considered 1

Second-Line Treatment

• Trastuzumab deruxtecan (T-Dxd) should be used as second-line therapy after progression on first-line HER2-targeted therapy 1
• This represents a strong recommendation based on moderate-quality evidence 1

HER2-Positive/Hormone Receptor-Positive Disease

For the subset with both HER2 and hormone receptor positivity, treatment options include 1:

• HER2-targeted therapy plus chemotherapy (strongest recommendation)
• Endocrine therapy plus trastuzumab or lapatinib in selected cases
• Endocrine therapy alone only in special circumstances (low disease burden, comorbidities, long disease-free interval)

The addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improves progression-free survival (44.3 months vs 29.1 months), though with increased neutropenia. 2

Timing Based on Recurrence

• If recurrence occurs ≤12 months after completing trastuzumab-based adjuvant treatment, follow second-line recommendations 1
• If recurrence occurs >12 months after completing adjuvant treatment, follow first-line recommendations 1

---

Triple-Negative Breast Cancer (TNBC)

For PD-L1-positive metastatic TNBC, add immune checkpoint inhibitor (atezolizumab plus nab-paclitaxel or pembrolizumab plus chemotherapy) as first-line therapy. 3

First-Line Treatment

• PD-L1-positive disease: Immune checkpoint inhibitor plus chemotherapy (strong recommendation, moderate evidence quality) 3
• PD-L1-negative disease: Single-agent chemotherapy rather than combination chemotherapy, except for symptomatic or immediately life-threatening disease 3
• Both platinum-based and non-platinum-based regimens are acceptable based on individual assessment 3

Later-Line Treatment

• Sacituzumab govitecan should be offered to patients who have received at least two prior therapies for metastatic disease (high-quality evidence) 3

BRCA-Mutated TNBC

• Patients with germline BRCA mutations previously treated with chemotherapy may be offered PARP inhibitors rather than additional chemotherapy 3

---

Hormone Receptor-Positive/HER2-Negative Breast Cancer

Single-agent chemotherapy should be used rather than combination chemotherapy for HR-positive/HER2-negative metastatic breast cancer, reserving combination regimens only for highly symptomatic or life-threatening disease. 3

Chemotherapy Selection

• Single-agent chemotherapy is preferred over combination regimens (strong recommendation, moderate evidence quality) 3
• Combination chemotherapy may be offered only when disease is highly symptomatic or life-threatening, where time allows only one potential chance for therapy 3

Alternative to Chemotherapy

• Patients with disease progression on endocrine therapy may be offered either endocrine therapy with or without targeted therapy, or single-agent chemotherapy 3
• For germline BRCA mutations no longer benefiting from endocrine therapy, PARP inhibitors may be offered rather than chemotherapy 3

Early-Stage HR-Positive/HER2-Negative Disease

• For high-risk early breast cancer, anthracycline and taxane-based chemotherapy in a dose-dense regimen remains standard of care 4
• For intermediate-risk disease requiring chemotherapy, anthracycline-free regimens could be the preferred option 4
• Dose-dense chemotherapy schedules are associated with significant reduction in recurrences and breast cancer mortality 4

---

Key Caveats

Common Pitfalls

• Do not use combination chemotherapy routinely in HR-positive/HER2-negative disease—this increases toxicity without proportional benefit except in crisis situations 3
• Do not continue chemotherapy indefinitely in HER2-positive disease—stop at 4-6 months and maintain HER2-targeted therapy alone 1
• Do not treat all HER2-positive/HR-positive patients identically—selected patients may benefit from endocrine-based approaches, particularly with palbociclib addition 1, 2

Testing Requirements

• PD-L1 testing is essential for TNBC to determine eligibility for immune checkpoint inhibitors 3
• Germline BRCA testing should be performed in appropriate candidates to identify those eligible for PARP inhibitors 3